In a bid to capitalize on the increasing prevalence of cannabis consumption in the US, pharmaceutical companies have introduced a new pill that claims to combat marijuana addiction. The experimental drug, AEF-0117, has shown promise in a small trial by reducing the addictive impact of THC, the primary psychoactive compound in cannabis. While the study published in the journal Nature Medicine may appear encouraging at first glance, a closer examination raises several concerns about the motives behind such pharmaceutical interventions.
After getting fired from multiple legal-sector jobs, Fergie Baby started secretly filming music videos inside…
Small growers, tighter margins, and a fight against corporate sameness are shaping the next phase…
Voter support for psychedelic research, therapy and prescription access all surged. Decrim didn’t move. A…
Burna Boy turned down $5 million to keep smoking. He launched his own cannabis brand…
Neuralink can simulate euphoria and stimulate the reward system on demand. But can a chip…
Chinese researchers at Shandong University just published a study in the Journal of Archaeological Science…